Bone Therapeutics has appointed Claudia D’August to its board of directors as a non-executive director. Claudia D'Augusta is a seasoned financial professional with more than 20 years’ experience in corporate finance, capital markets and M&A. She is currently chief financial officer at TiGenix and is part of the management team at TiGenix, which Takeda has announced its intention to acquire for EUR 520 million. Prior to TiGenix, Claudia D'Augusta held various other senior financial positions across a number of international public and private companies.